Quality of life in colorectal cancer patients treated with doxorubicin and a multi-drug resistance (MDR) modulator (SDZ PSC-833): A pilot study

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2933-2936

  Norum, Jan ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Colorectal cancer; Multi drug resistance; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; VALSPODAR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DYSPNEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL ASPECT; VOMITING;

EID: 0031814726     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hardcastle JD, Robinson MHE : Screening of colorectal cancer. Eur J Cancer 28A: 1778-1780, 1992.
2. Cancer in Norway 1994: The Cancer Registry of Norway, Institute for Epidemiological Cancer Research, Oslo 1997.
3. Tveit KM, Dahl O, Gerner T: Chemotherapy in colorectal cancer. J Nor Med Assoc 116: 357-360, 1996.
4. De Vries EG, Pinedo HM: Clinical implications of multidrug resistance to chemotherapy. Cancer Treat Res 57: 171-186, 1991.
5. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42: 277, 1991.
6. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155, 1990.
7. Zacherl J, Hamilton G, Thalhammer T, Riegler M, Cosentini EP, Ellinger A, Bischof G, Schweitzer M, Teleky B, Koperna T, Wenzl E: Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporin A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol 34: 125-132, 1994.
8. Sandoz Pharma: Clinical study PSC B208-E-00. An open-label, single arm phase 1/2 study to determine the safety, tolerability and activity of doxorubicin in combination with the multidrug resistance modulator SDZ PSC 833 in front-line treatment of subjects with advanced colorectal cancer. Novartis Pharma AG, Switzerland 1996.
9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner A, Fleisman SB, deHaes JC, for the European Organisation for Research and Treatment of Cancer Study Group on Quality of Life. The European Organisation for Research and Treatment of Cancer QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
10. Westervelt A, Williams KM, Rosen DM, Egorin MJ, Fracasso PM: A phase I study of Taxol and intravenous SDZ PSC 833 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 16: 254, abstract 900, 1997.
11. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73: 556-562, 1994.
12. Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T: Impact of protracted venous infusion fluorouracil with or without interferon alpha-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317-2323, 1995.
13. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L: PSC 833. Initial clinical results in refractory ovarian cancer patients. In: Van Oesterom A, Emerging clinical strategies in cancer treatment. ECCO 9 Novartis satelite symposium, Hamburg 1997; 8-9.
14. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L: SDZ PSC 833/paclitaxel in ovarian carcinoma: a phase II trial with renewed responses. Proc Am Soc Clin Oncol 16: 351, abstract 1254, 1997.
15. Jone G, van Rensburg CEJ. Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to paclitaxel and taxotere. Eur J Cancer 33: (Suppl 8) 179, abstract 804, 1997.
16. Charnick SB, Fracasso Å, Egorin M, Sonneveld P, Bleehan N, Giaccone G, Niederberger W, Smith HT, Pearce T, Sikic BI. Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase I trials with chemotherapeutic agents. Eur J Cancer 33: (Suppl 8) 173, abstract 775, 1997.